Loading...
XNAS
DCTH
Market cap537mUSD
Jun 16, Last price  
15.43USD
1D
0.59%
1Q
14.81%
Jan 2017
-100.00%
IPO
-100.00%
Name

Delcath Systems Inc

Chart & Performance

D1W1MN
XNAS:DCTH chart
P/E
—
P/S
17.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
305.83%
Rev. gr., 5y
81.38%
Revenues
31m
+1,402.03%
0000000346,000790,0001,069,0001,747,0001,992,0002,715,0003,407,0001,580,0001,646,0003,555,0002,719,0002,065,00031,017,000
Net income
-26m
L-44.66%
-2,864,619-10,951,605-3,663,506-6,864,885-22,056,592-46,683,645-30,885,000-51,868,000-30,324,000-17,381,000-14,704,000-17,971,000-45,117,000-19,222,000-13,627,000-24,485,000-26,757,000-39,163,000-47,678,000-26,386,000
CFO
-19m
L-40.22%
-3,019,217-9,202,451-5,569,197-6,723,277-10,462,242-24,082,714-37,372,000-50,006,000-34,102,000-15,552,000-16,420,000-14,213,000-15,398,000-14,732,000-23,690,000-22,868,000-22,604,000-24,950,000-31,251,000-18,681,000
Earnings
Aug 04, 2025

Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
URL
https://delcath.com/
IPO date
Oct 19, 2000
Employees
52
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
31,017
1,402.03%
2,065
-24.05%
2,719
-23.52%
Cost of revenue
13,874
18,137
19,269
Unusual Expense (Income)
NOPBT
17,143
(16,072)
(16,550)
NOPBT Margin
55.27%
Operating Taxes
2,655
Tax Rate
NOPAT
17,143
(16,072)
(19,205)
Net income
(26,386)
-44.66%
(47,678)
21.74%
(39,163)
46.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,271
23,083
10,857
BB yield
-2.12%
-34.19%
-34.02%
Debt
Debt current
105
10,224
8,032
Long-term debt
1,971
37
8,028
Deferred revenue
Other long-term liabilities
766
6,388
1,144
Net debt
(51,157)
(22,193)
8,389
Cash flow
Cash from operating activities
(18,681)
(31,251)
(24,950)
CAPEX
(559)
(58)
(209)
Cash from investing activities
(981)
(19,709)
(209)
Cash from financing activities
39,410
51,778
10,143
FCF
1,281
(15,820)
(18,940)
Balance
Cash
53,233
32,454
7,671
Long term investments
Excess cash
51,682
32,351
7,535
Stockholders' equity
(531,135)
(504,799)
(457,467)
Invested Capital
601,685
537,188
468,626
ROIC
3.01%
ROCE
24.30%
EV
Common stock shares outstanding
28,511
16,230
8,865
Price
12.04
189.42%
4.16
15.56%
3.60
-53.55%
Market cap
343,277
408.43%
67,517
111.57%
31,913
-42.37%
EV
292,120
45,324
40,302
EBITDA
17,372
(15,944)
(16,418)
EV/EBITDA
16.82
Interest
1,439
2,685
Interest/NOPBT